733 Industrial Road
San Carlos, CA 94070
Biotech and Pharmaceutical
Accelero Biostructures is capitalizing on over 20 years of structural genomics and structural biology expertise using high-throughput protein X-ray crystallography with our ABS and ABS-OneStep platforms.
ABS provides a unified pipeline of gene-to-structure protein X-ray crystallography solutions aimed at the pharmaceutical and biotechnology industries to support structure-based drug discovery and protein engineering.
ABS-OneStep is our next-generation platform, being developed with SBIR Phase II funding from NIH, focused on using fragment-based drug discovery (FBDD) to develop novel therapeutics. FBDD is also an effective starting point in the discovery of novel chemical entities for “non-druggable” targets. Fragment library screening with ABS-OneStep resolves key bottlenecks in conventional FBDD approaches. ABS-OneStep provides an extremely sensitive, efficient, single-step approach for determining fragment binding hits and elucidating their 3D binding site structures using protein X-ray crystallography to determine molecular interactions in the broadest interaction range including weak affinities usually seen for fragment binding.